Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2026-03-30 Environmental & Social …
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2025年度环境、社会及公司治理(ESG)报告
Environmental & Social Information Classification · 100% confidence The document is titled "2025 年度 环境、社会及公司治理(ESG) 报告" which translates to "2025 Environmental, Social and Corporate Governance (ESG) Report". It covers the company's ESG performance for the year 2025, including governance structure, environmental management, social responsibility, and sustainability initiatives. The content includes detailed sections on sustainable development governance, environmental performance, social contributions, and governance practices. The document is comprehensive and contains substantive data and analysis related to ESG factors. It is not a financial report like an annual or quarterly report, nor is it an announcement or certification. The document fits the definition of an Environmental & Social Information report (ESG report). Therefore, the appropriate classification is "SR" (Environmental & Social Information). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement.
2026-03-30 Chinese
关于毕马威华振会计师事务所（特殊普通合伙）的履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report by the company's audit committee on the performance of the external audit firm KPMG Huazhen for the fiscal year 2025. It discusses the audit firm's qualifications, the audit process, communication with management, and the audit opinion issued. The document includes details about the audit of the 2025 annual financial statements and internal controls, and confirms the issuance of an unqualified audit report. The content focuses on the audit report and the audit firm's performance rather than the full annual report itself. The document length is 1896 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, it fits best as an Audit Report / Information (AR) rather than an Annual Report (10-K) or a Report Publication Announcement (RPA). FY 2025
2026-03-30 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司使用向特定对象发行A股股票募集资金置换预先投入募投项目及已支付发行费用的自筹资金的核查意见
Regulatory Filings Classification · 62% confidence The document is a sponsor’s verification opinion (“核查意见”) under listing rules concerning the replacement of self-raised funds with proceeds from a specific A-share issuance. It is a compliance/certification filing by the sponsor rather than a full financial report, investor presentation, or management announcement. It does not fit categories like Annual Report, Interim Report, or Share Issue announcement directly, so it falls under the general Regulatory Filings (RNS) category.
2026-03-30 Chinese
关于续聘2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the reappointment of the audit firm KPMG Huazhen for the fiscal year 2026. It details the background of the audit firm, the qualifications of the auditors, their independence, audit fees, and the approval process by the audit committee, board of directors, and shareholders. The document does not contain any actual financial statements or audit reports but is a formal announcement about the appointment of the audit firm for the upcoming audit period. The document length is relatively short (2597 characters) and it serves as a notice rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and not the audit report, it is best classified as Audit Report / Information (AR). FY 2026
2026-03-30 Chinese
2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2025 by Shenzhen Microchip Biotechnology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, evaluation scope, standards, and conclusions. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal controls, excluding full annual reports. The document length (4008 characters) is sufficient for a detailed report but not overly long, consistent with an internal control evaluation report rather than a full annual report (10-K) or interim report (IR). Therefore, the best classification is AR with high confidence. FY 2025
2026-03-30 Chinese
自愿披露关于西格列他钠二甲双胍缓释片获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microcore Biotech Co., Ltd. regarding the approval of a clinical trial application for a new drug by the National Medical Products Administration. It contains no financial data, no financial statements, no management discussion of financial results, nor any regulatory certifications or voting results. It is an official announcement about a regulatory approval related to drug clinical trials, which is a regulatory update but not a financial report or management report. The document length is short (1397 characters) and it is an announcement of a regulatory event. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-03-16 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.